Sanofi Invests $91 Million in BioNTech to Advance mRNA-Based Cancer Immunotherapy

Recently, VCBeat (WeChat official account: vcbeat) learned from foreign media that German biopharmaceutical company BioNTech has received a $91 million investment from Sanofi. The investment agreement between the two parties indicates that BioNTech and Sanofi will jointly develop cancer immunotherapies.

It is reported that Sanofi has been collaborating with BioNTech since late 2015. Sanofi made an upfront payment of $60 million to secure the patent rights to five immunotherapy candidates in the discovery stage. As these immunotherapies advance, Sanofi will pay BioNTech milestone payments of up to $300 million for each research program, making this agreement a potentially significant business opportunity for both companies.

BioNTech AG is Europe’s largest privately held biopharmaceutical company, pioneering personalized treatments for cancer and other diseases. The company integrates all building blocks of personalized immunotherapies—diagnostics, drug development, and manufacturing—into a single platform. Its cutting-edge technologies include personalized mRNA therapeutics, innovative chimeric antigen receptor (CAR) and T-cell receptor (TCR) products, and novel checkpoint immunomodulators.

The investment agreement signed by BioNTech and Sanofi indicates that the drug developed through this collaboration is the most advanced candidate under the agreement, consisting of mRNA encoding immunomodulatory cytokines. Upon intratumoral injection, the synthetic mRNA induces the production of immunomodulatory molecules, thereby eliciting an immune response against tumor-specific antigens. Sanofi and BioNTech stated that while anti-vector immunity in distant tissues may impact viral gene therapy and oncolytic virus therapy, this approach can avoid such effects.

BioNTech and Sanofi have not yet generated clinical data to demonstrate that their drugs can meet the aforementioned requirements and launch a potent, highly targeted attack against tumors. However, reports indicate that both companies are conducting solid tumor trials for their lead drug candidates, suggesting that initial clinical data will be available soon.

In less than three years, this leading project has progressed from concept to clinical development, carving out a distinct niche for Sanofi and BioNTech in their respective fields.

Sanofi, headquartered in Paris, France, is the world’s fourth-largest pharmaceutical company (ranking behind Pfizer and GlaxoSmithKline). Sanofi is dedicated to the research, development, manufacturing, and sales of pharmaceutical products, with its portfolio primarily covering seven therapeutic areas: cardiovascular diseases, thrombosis, oncology, diabetes, central nervous system disorders, general medicine, and vaccines.

Sanofi has consistently upheld its commitment to China. In 1982, Sanofi established an office in China, becoming one of the first multinational pharmaceutical companies to enter the Chinese market. Currently, Sanofi employs more than 9,000 people in China, with its China headquarters located in Shanghai and additional offices in multiple cities including Beijing, Tianjin, and Shenyang. It is one of the fastest-growing healthcare companies in China.

mRNA, or messenger RNA, is a major class of RNA molecules that transmit genetic information from DNA to ribosomes. Within the ribosomes, mRNA specifies the amino acid sequence of protein products encoded by genes. RNA polymerase transcribes precursor mRNA (pre-mRNA) into mature, processed mRNA. This mature mRNA is then translated into amino acid polymers, known as proteins.